Abstract
Anthracyclines have a central role in the management of non-Hodgkin's lymphoma (NHL). The cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) treatment regimen has been the standard of care for more than 20 years. Further improvements have been made to the efficacy of this chemotherapy by reducing the dosing interval and adding rituximab to the regimen. A major limitation to the use of anthracyclines is the development of cardiotoxicity as a late adverse event. Strategies to reduce cardiac events include changes to the dosing schedule for doxorubicin, use of the chelating agent dexrazoxane and the use of liposome-encapsulated doxorubicin. This latter strategy has demonstrated good efficacy and reduced cardiotoxicity in patients with NHL, including those at risk of developing cardiac effects.
References
Nov 1, 1979·Annals of Internal Medicine·D D Von HoffF M Muggia
Aug 30, 1969·British Medical Journal·G BonadonnaF Fossati-Bellani
Feb 1, 1982·Annals of Internal Medicine·S S LeghaE J Freireich
Apr 8, 1993·The New England Journal of Medicine·R I FisherT P Miller
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
May 27, 2003·Cancer·Sandra M SwainMichael S Ewer
Feb 18, 2004·The Breast : Official Journal of the European Society of Mastology·K L Cheung, J F Robertson
Feb 26, 2004·Blood·Michael PfreundschuhUNKNOWN German High-Grade Non-Hodgkin's Lymphoma Study Group
Mar 16, 2004·Blood·Michael PfreundschuhUNKNOWN German High-Grade Non-Hodgkin's Lymphoma Study Group
Jun 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laurie H SehnJoseph M Connors
May 2, 2006·The Lancet Oncology·Michael PfreundschuhUNKNOWN MabThera International Trial Group
Jun 7, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas M HabermannSandra J Horning
Aug 2, 2006·Clinical Lymphoma & Myeloma·Anil TulpuleAlexandra M Levine
Oct 21, 2006·The Cochrane Database of Systematic Reviews·E C van DalenL C M Kremer
Jul 27, 2007·Hematological Oncology·Luigi RigacciAlberto Bosi
Jan 30, 2008·The Lancet Oncology·Michael PfreundschuhUNKNOWN German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
Apr 22, 2008·The Cochrane Database of Systematic Reviews·E C van DalenL C M Kremer
Oct 13, 2009·The Cochrane Database of Systematic Reviews·Elvira C van DalenLeontien Cm Kremer
Dec 17, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S LuminariM Federico